IRIDEX Q2 Loss Widens Y/Y as Retina Weakness Weighs, Stock Down 15%
IRIX's Q2 loss per share widens year over year and revenues decline as Middle East disruptions and reduced sell-through in China weigh on retina sales, offsetting continued growth in the Cyclo G6 product family.
Zacks
Full Transcript: Iridex Q2 2026 Earnings Call
Iridex (NASDAQ:IRIX) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call.
Benzinga APIs provide real-time access to earnings call transcripts and financial data.read more...
Benzinga
IRIX Stock Up 4% As Q1 Loss Narrows Y/Y on Glaucoma Product Growth
IRIDEX posts a narrower year-over-year net loss per share in Q1'26 as strong glaucoma product sales and lower operating costs helped offset weakness in retina sales and supply-chain disruptions.
The Zacks Analyst Blog Microsoft, AbbVie, BHP, CBL & Associates Properties and IRIDEX
Microsoft, AbbVie and BHP anchor today???s top analyst reports, highlighting AI growth, drug pipeline strength and rising commodity output shaping outlooks.
Zacks
Top Analyst Reports for Microsoft, AbbVie & BHP
Microsoft rides AI and Azure growth, but slowing cloud guidance, capacity limits, and rising competition cast a shadow on its momentum.
Zacks
Iridex's Q4 Loss Narrows Year Over Year on Retina Sales Growth
IRIX incurs narrower year-over-year loss per share in Q4 as growth in retina systems and glaucoma probes boosts revenues, though margins remain pressured by higher costs.